86 results about "Inflammatory infiltration" patented technology

The invention discloses a nano-enzyme microneedle system for remodeling a diabetes wound microenvironment to promote healing and a preparation method of the nano-enzyme microneedle system. The nano-enzyme microneedle system comprises nano-enzyme and a microneedle carrier, the nano-enzyme is prepared by a self-assembly method and is loaded in the microneedle carrier; the microneedle carrier is composed of a hydrogel matrix and is molded into a microneedle array through 3D printing; according to the system, the nano-enzyme can be delivered to the corium layer by penetrating the cuticle of the skin through the microneedle. The traditional Chinese medicine composition has the advantages that ROS (reactive oxygen species) is efficiently removed, oxidative stress injury induced by high glucose (HG) is relieved, immune cell polarization is regulated, inflammatory factor release is regulated and controlled, the chronic inflammation state of wound surfaces is relieved, cell proliferation and migration are promoted, neovascularization is accelerated, the healing speed of the diabetic wound surfaces is obviously increased, inflammation infiltration is reduced, granulation tissue formation and collagen deposition are obviously improved, and the effect of treating diabetes mellitus is achieved. And no systemic toxicity is observed. Through the synergistic effect of resisting oxidation, resisting inflammation and promoting angiogenesis, the pathological microenvironment of the diabetic wound is effectively improved.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating acute respiratory distress syndrome and a preparation and a preparation method thereof, and the traditional Chinese medicine composition is prepared from the following raw materials: 12-30g of ginseng, 6-30 parts of rheum officinale, 9-30 parts of salvia miltiorrhiza and 3-15 parts of semen lepidii. Pharmacological experiments prove that the traditional Chinese medicine composition can improve lung inflammation infiltration to different degrees, improve lung tissue structure disorder and relieve pulmonary edema, and the clinical death rate is remarkably reduced in clinical application; the prepared preparation, especially granules, can be stored for 36 months for a long time, and is suitable for further industrial mass production.

The invention provides application of Ulixertinib in treatment of lung tissue inflammation caused by novel coronavirus, and the Ulixertinib can effectively relieve the lung inflammatory infiltration degree after infection of the novel coronavirus, reduce the expression level of cytokines, chemotactic factors or NETs related proteins and inhibit formation of NETs. The invention provides a brand new treatment strategy for novel coronavirus infection, especially severe lung tissue inflammation caused by multiple infection of novel coronavirus.

The invention discloses a biological medicine application of luwulinine, and provides and verifies that luwulinine can inhibit disulfiram death of cells for the first time, so that luwulinine can be used for preventing or treating hepatic ischemia reperfusion injury. Experimental data show that the luteiniine can relieve liver function injury after reperfusion with cell apoptosis, tissue inflammation infiltration and tissue fibrosis as manifestations, and a new direction is provided for mechanism research and prevention and treatment of hepatic ischemia reperfusion injury.

The invention discloses a Parabacteroides goldsteinii bacterium and application of a metabolite of the Parabacteroides goldsteinii bacterium in treatment of metabolism-related steatohepatitis and fibrosis related to the metabolism-related steatohepatitis. According to the application disclosed by the invention, firstly, through biological analysis, the fact that Parabacteroides goldsteinii and a metabolite 7-Sulfocholic acid of Parabacteroides goldsteinii are closely related to the progress of MASH related fibrosis is determined; furthermore, functional intervention is implemented in a CDAHFD model, the MASH and the related fibrosis process of the MASH can be remarkably inhibited by supplementing Parabacteroides goldsteinii or 7-Sulfocholic acid, the MASH and the related fibrosis process of the MASH can be relieved, liver fatty degeneration, inflammatory infiltration and collagen deposition can be relieved, and further conversion and application feasibility can be achieved.

Chronic obstructive pulmonary disease (COPD) remains a major cause of morbidity and mortality worldwide. Acute exacerbation of COPD (AE-COPD) in patients are mostly due to respiratory infection and are associated with an inexorable decline in lung function, enhanced oedema as well as airway and systemic inflammation. Previous results show that treatment with anti-IL-20Rb blocking antibodies increased the bacterial clearance in control mice infected by S. pneumoniae and protected CS-exposed mice from bacterial infection, by decreasing the bacterial burden and the inflammatory infiltrate. Therefore there is an interest for generating monoclonal antibodies specific for IL-20Rb with a neutralizing activity for their use in the treatment of AE-COPD. The present invention fulfills this need by providing antibodies having specificity for IL-20Rb.

The invention discloses application of a substance taking MANF as a target spot in preparation of a medicine for treating non-alcoholic steatohepatitis. The research finds that the expression of the MANF in liver tissues of a fatty liver patient and a non-alcoholic steatohepatitis model mouse is obviously up-regulated, and the weight, liver lipid accumulation and inflammatory infiltration of the NASH mouse can be obviously reduced by specifically knocking out the MANF by the macrophage, so that the MANF in the macrophage plays an important role in the NASH pathological process.

The application discloses an active polypeptide and application thereof in treating diabetic peripheral neuropathy, and belongs to the technical field of biological polypeptide drugs. An amino acid sequence of the active polypeptide is QVWPDGFVGLAKLWI, which is obtained by step-by-step enzymatic extraction and purification from Morus alba L. which is a homology of medicine and food. The polypeptide can significantly inhibit oxidative stress, inflammatory infiltration and cell apoptosis of Schwann cells induced by a high-sugar environment, and repair the function of damaged nerve cells. Meanwhile, the polypeptide can effectively improve abnormal sciatic nerve conduction function of a diabetic model mouse. The active polypeptide can be used for preparing a drug for treating diabetic peripheral neuropathy, and provides a new candidate drug and research and development direction for the targeted treatment of diabetic peripheral neuropathy.

The invention provides an application of a Ly6G antibody in treatment of pneumonia caused by novel coronavirus, and the Ly6G antibody can effectively reduce the lung inflammatory infiltration degree after novel coronavirus infection, reduce the expression level of cytokines, chemotactic factors or NETs related proteins, and inhibit formation of NETs. The invention provides a brand new treatment strategy for novel coronavirus infection, especially severe pneumonia caused by multiple infection of novel coronavirus.

The invention discloses application of cynarin in preparation of a medicine for resisting respiratory syncytial virus. The cynarin is polyphenolic acid cynarin, and the respiratory syncytial virus is an RSV-A2 strain; the compound can effectively inhibit replication of respiratory syncytial viruses, is a monomer component of natural medicinal plants, is clear in structure, stable in chemical property, easy in quality control and free of obvious toxic and side effects, can effectively resist inflammation while serving as an active component of a natural small-molecule antiviral drug, and has a broad application prospect. Viral lung inflammatory infiltration and lung injury caused by the respiratory syncytial virus are relieved.

The invention discloses a cascade targeted drug delivery system as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention designs a drug delivery system with a cascade targeting function, and the drug delivery system is used for delivering a phosphodiesterase 4 inhibitor A5. Through polypeptide modification and exosome fusion, phagocytosis and ingestion of cells to a drug delivery system are promoted, and the bioavailability of the drug is significantly improved. The drug delivery system shows excellent in-vivo lung targeting, can effectively inhibit the aggravation of inflammatory infiltration in the lung, and plays a role in treating acute lung injury. The invention provides a new strategy for improving the targeting property and the utilization rate of the medicine, provides a new medicine for treating the acute lung injury, and has a wide application prospect and an extremely high application value.

The application discloses a kind of compositions for treating radiation enteropathy and application thereof, belong to medical technology field.The composition includes the following components: anemarrhena asphodeloides B4, obakunine, berberine, aesculetin, fraxinellone and fraxinellin.The composition has no toxic side effects, has good safety, can reduce the inflammatory infiltration of intestinal epithelial cells, reduce intestinal epithelial cell apoptosis, protect intestinal barrier and protect intestinal oxidative damage by regulating NF-κB, Caspase 9 / 3 and NRF2 pathway, and then multi-component, multi-pathway jointly play the efficacy of treating radiation enteropathy.The problem that there is no effective drug for treating radiation enteropathy in the prior art is solved.

Disclosed are a myocarditis-targeted radionuclide molecular probe, a preparation method therefor, and an application thereof. The myocarditis-targeted radionuclide molecular probe includes a DPP4 inhibitor, a bifunctional chelator covalently bonded to an amino group of the DPP4 inhibitor, and a metallic radionuclide coordinately bonded to the bifunctional chelator. The myocarditis-targeted radionuclide molecular probe provided by the present disclosure exhibits high specificity and good targeting capability, and demonstrates significant uptake in myocardial inflammatory cells, and low uptake in non-target tissues. Characterized by high resolution and sensitivity of imaging, the myocarditis-targeted radionuclide molecular probe is applied for early diagnosis of cardiac inflammatory infiltration severity, therapeutic efficacy evaluation, prognosis assessment and the like, and has promising clinical and application prospects in the field of non-invasive nuclear medicine diagnosis and treatment as a myocarditis imaging agent.

The present invention provides use of lifitegrast in the preparation of a drug for treating retinal artery occlusion injury. Lifitegrast can effectively reduce retinal artery occlusion injury and apoptosis of retinal ganglion cells and has the effect of inhibiting inflammatory infiltration in the retina and activation of microglia. Moreover, lifitegrast has the effect of reducing retinal ganglion cell injury. Lifitegrast can be used for related diseases such as neuroinflammatory injury caused by retinal artery occlusion.

The invention relates to the technical field of medicines, in particular to application of an integrin beta3 inhibitor RGDfK in preparation of a medicine for treating metabolic dysfunction related fatty liver diseases. The RGDfK provided by the invention can inhibit palmitoylation and membrane localization of CD36 in liver tissues of mice with fatty liver diseases related to metabolic dysfunction induced by high fat diet feeding, so that lipid uptake of the liver is inhibited. Experimental results show that RGDfK can improve obesity and insulin resistance of mice with metabolic dysfunction-related fatty liver diseases, can improve fat accumulation, fibrosis and inflammatory infiltration of liver tissues of the mice with fatty liver diseases, and is expected to become a new medicine for treating the metabolic dysfunction-related fatty liver diseases.

This invention relates to the field of congenital heart disease treatment technology, and discloses the application of sapropterin in the prevention and treatment of bisphenol fluorene-induced congenital heart disease in fetuses. The congenital heart disease includes cardiac structural defects, heart failure, or cardiomyocyte lesions, specifically selected from ventricular septal defects, atrial septal defects, tetralogy of Fallot, myocardial hypertrophy, decreased cardiac ejection fraction, decreased short-axis contraction rate, cardiomyocyte ferroptosis, myocardial tissue inflammatory infiltration, or myocardial collagen fibrosis. Sapropterin is used as a direct supplement to biological tetrahydropterin (BH4). Through exogenous intervention, it precisely reverses the endogenous BH4 deficiency caused by bisphenol fluorene exposure, restores the expression of GTP cyclase 1 (GCH1) and the dynamic balance of RNA m6A, and upregulates the level of YTH domain family protein 2 (YTHDF2), thereby blocking ferroptosis signal transduction, reducing oxidative stress and inflammatory response, and inhibiting the process of myocardial tissue fibrosis at the molecular level.

The invention relates to application of cepharanthine in preparation of medicines for preventing or treating metabolic dysfunction related fatty liver diseases (Metabolic-associated fatty liver diseases), and particularly relates to application of cepharanthine in preparation of medicines for preventing or treating metabolic dysfunction related fatty liver diseases (Metabolic-associated fatty liver diseases). The invention relates to an application of MASLD in a medicine, and belongs to the technical field of biological medicines. In an in-vivo experiment, a mouse MASLD model is established by adopting methionine choline deficiency diet induction, and the treatment effect of cepharanthine on MASLD is researched. Experimental results show that the cepharanthine can significantly reduce the levels of triglyceride, glutamic-pyruvic transaminase, glutamic oxalacetic transaminase and other indexes of MASLD mice; a pathological detection result shows that cepharanthine can effectively reduce liver lipid deposition and inflammatory infiltration. In-vitro experiments prove that cepharanthine can effectively reduce the content of free fatty acid (Free Fatty Acid); fFA (Fatty Acid) induced HepG2 (HepG2) cell lipid accumulation and lipopolysaccharides (lipopolysaccharides) induced HepG2 cell lipid accumulation and lipopolysaccharides (FFA) induced HepG2 cell lipid accumulation; the THP-1 cell inflammatory response is induced by LPS (Lipopolysaccharide). In conclusion, the cepharanthine shows remarkable anti-lipid accumulation and anti-inflammatory effects in in-vivo and in-vitro experiments, can be used for preparing the medicine for preventing or treating MASLD, and has a wide application prospect.

The invention discloses a supramolecular compound and a preparation method and application thereof.The supramolecular compound is carrier-free nanoparticles (CDN) obtained by conducting molecular self-assembly on tripterine (CeL) and demethylwedelolactone, and experiments show that the CDN can effectively relieve clinical symptoms, inflammation infiltration and bone erosion. Besides, the CDN can be transferred to an inflammation part of rheumatoid arthritis (RA) in a targeted manner, so that bone degenerative change and joint skeleton damage can be remarkably reduced, the inflammation part is targeted, the expression of proinflammatory cytokines is reduced, the drug concentration of the affected part is improved, and the toxic and side effects of the tripterine are reduced. The research provides a new strategy for improving the curative effect and safety of the traditional Chinese medicine, and provides a brand new solution for RA treatment.

The invention relates to application of hispidulin or pharmaceutically acceptable salts, esters and solvates thereof in preparation of medicines for treating lupus nephritis. The invention develops a new application of the hispidulin, and proves the treatment effect of the hispidulin on lupus nephritis. Meanwhile, the invention verifies that the hispidulin can obviously improve the renal function indexes (including reducing urine protein, blood urea nitrogen and serum creatinine, increasing serum albumin and improving lipid metabolism) of lupus nephritis, can relieve renal pathological injuries (including reducing glomerular mesangial hyperplasia, basilar membrane thickening, renal tubule dilatation and interstitial inflammation infiltration), and can improve the renal function indexes of lupus nephritis. Kidney immune complex deposition can be reduced (including reduction of deposition of kidney IgG and complement C3), meanwhile, it is found for the first time that angiogenin-like protein 4 (Angptl4) is a key action target for treating lupus nephritis by means of the homospidulin, and the homospidulin plays a kidney protection role by down-regulating Angptl4 expression.

A novel disulfide biphenol ether compound and its preparation method and application for treating inflammatory skin diseases, the structural formula of the disulfide biphenol ether compound is: biphenyl diester is first dissolved in anhydrous tetrahydrofuran solvent, lithium aluminum hydroxide is added, quenched, filtered, extracted with dichloromethane, water is added to quench the reaction, extracted with dichloromethane, the organic phases are combined, after removing residual moisture, the reduced pressure rotary evaporation and recrystallization are removed to obtain intermediate 2; intermediate 2 and potassium thioacetate are added to solvent N, N-dimethylformamide and extracted, the organic phases are combined, and the solvent is evaporated and concentrated to obtain a light intermediate 3; intermediate 3 is dissolved in anhydrous methanol, sodium methoxide is added, stirred, extracted with ethyl acetate, and the organic phases are combined to obtain. The disulfide biphenyl compound prepared by the present invention has good anti-inflammatory ability, can effectively reduce inflammatory infiltration in tissue, improve the inflammatory phenotype of animal models, and can prevent and treat inflammatory skin diseases.

The application relates to the technical field of aquatic virus prevention and treatment, and particularly discloses application of YTX in preparation of a medicine for preventing and treating SCRV infection. The application verifies the prevention and treatment effects of YTX on SCRV infection through fish body level experiments. The experimental results show that, in a safe concentration range, YTX can significantly improve the survival rate of fish after SCRV infection by being administered through soaking or injection, the relative protection rate is more than 85%; the virus load in target organs such as kidneys and spleens is significantly reduced, the virus copy number is reduced by 2-3 logarithmic levels; and the pathological damage such as tissue necrosis and inflammatory infiltration caused by the virus is effectively reduced. The application verifies the anti-SCRV effect of YTX at the fish body level for the first time, provides key data support for development and application of YTX as a new aquatic antiviral preparation, and has important industrial application value.

A cannabidiol composite reagent for resisting muscle aging belongs to the technical field of biomedicine, and is characterized in that 0.6 g of cannabidiol is firstly weighed and dissolved in 4 mL of edible linoleic acid, and the cannabidiol composite reagent is prepared by uniformly mixing on a vortex oscillator; research finds that the cannabidiol composite reagent can reduce muscle fiber fracture, inflammation infiltration and cell deformation and swelling during aging and increase the muscle fiber area, and experiments prove that the cannabidiol composite reagent can resist oxidative damage in the muscle aging process and relieve muscle tissue aging.

The invention discloses application of a traditional Chinese medicine composition in preparation of a medicine for preventing and treating bacterial liver injury of chicks. The traditional Chinese medicine composition is prepared from herba artemisiae scopariae and radix scutellariae. For bacterial infection and immunological liver injury triggered by endotoxin, through compatibility and synergy of'one clearing and one benefiting 'of two medicines, pathogen stimulation and immune overresponse links are intervened at the same time, and growth inhibition caused by liver injury is blocked. The traditional Chinese medicine composition is extracted and prepared into oral liquid, powder and other dosage forms, and then is applied to chicks at the age of 6-12 days. Experiments prove that the traditional Chinese medicine composition can significantly reduce the activity of liver injury markers such as serum ALT and AST, alleviate liver inflammatory infiltration and necrosis, can reverse the decrease of average daily gain caused by liver injury, synchronously realizes liver injury repair and growth performance guarantee, adapts to resistance reduction / forbidden resistance trends, and has a broad application prospect. And a safe and effective solution is provided for preventing and treating bacterial liver injury in the early brooding stage of broilers.

The present invention discloses a strain of Leuconostoc mesenteroides jonggajibkimchii subspecies, the deposit number of the strain is CGMCC No.30904, the deposit date is June 7, 2024, and the deposit classification is named Leuconostoc mesenteroides Leuconostoc mesenteroides The strain provided by the present invention is harmless to animals and has the significant efficacy of alleviating inflammatory infiltration of lung tissue caused by bronchial asthma, reducing the release of serum IgE and Th2 cytokines, inhibiting excessive macrophage replacement activation in the lungs, and improving allergic airway inflammation.

The invention discloses a fusion protein CTB-3MOG34-56, a DNA (deoxyribonucleic acid) molecule, a recombinant vector and application of the fusion protein CTB-3MOG34-56. Belongs to the technical field of biological medicine. The CTB-3MOG34-56 fusion protein is constructed for the first time, and it is proved that the CTB-3MOG34-56 fusion protein can significantly inhibit disease progression of EAE mice through oral administration or nasal mucosa administration, reduce inflammatory infiltration of a central nervous system and significantly inhibit Th17-mediated inflammation (IL-17A and IL-6) and TNF-alpha pathways at the same time; and the TGF-beta is specifically up-regulated to enhance the immunosuppression function of Treg. The fusion protein has the effects of prophylactic immunoregulation and therapeutic neuroprotection, provides a new potential candidate drug for the treatment of experimental autoimmune encephalomyelitis and multiple sclerosis, and has a wide clinical application prospect.

The application relates to a compound traditional Chinese medicine composition for treating dermatitis of tumor patients, which is prepared from the following raw materials in parts by weight: 20-40 parts by weight of Huangqi, 5-15 parts by weight of Wumei, 5-15 parts by weight of Baishao, 5-15 parts by weight of Dilong and 10-20 parts by weight of Danshen, and a preparation method thereof is disclosed. The application can obviously improve the clinical dermatitis score related to skin lesions, reduce the spleen coefficient index, and also has the functions of reducing the epidermal thickness and inflammatory infiltration such as mast cells in the dermis, and reducing the inflammatory factor level in the skin lesions, which shows that the application can treat dermatitis of tumor patients.

The application discloses application of a Corydalis yanhusuo extract in preparation of an anti-allergic drug and belongs to the technical field of anti-allergic drug preparation. The treatment effect of the drug on allergic diseases is evaluated by comparing P815 cell degranulation and inflammatory factor release, the inflammatory infiltration degree of a local skin allergic reaction of a mouse, and the allergic symptoms of a mouse as a whole, so that it is determined that the Corydalis yanhusuo extract can be used for preparation of an anti-allergic drug. The Corydalis yanhusuo extract can effectively alleviate the local and systemic allergic reaction symptoms of a mouse, and reduce mast cell degranulation, and has a significant improvement effect on symptoms caused by allergic reactions.

The application discloses application of a benzofuro[3,2-c]quinolinone compound in preventing and treating metabolic dysfunction related steatohepatitis. The compound P82, i.e. 3,8-dihydroxybenzofuro[3,2-c]quinolin-6(5H)-one, is prepared through synthesis and purification of an intermediate, and can obviously improve liver steatosis, inflammatory infiltration and fibrosis in a metabolic dysfunction related steatohepatitis model induced by HFHC, thereby effectively delaying the progress of metabolic dysfunction related steatohepatitis. Meanwhile, the compound can improve lipid accumulation of liver cells induced by oleic acid and palmitic acid, and is expected to be developed into a new drug for preventing and treating metabolic dysfunction related steatohepatitis.

The invention discloses a new application of benzbromarone or pharmaceutically acceptable salt thereof in preparation of a medicine for treating pulmonary fibrosis. The invention belongs to the technical field of medicine. Experimental results show that the benzbromarone can significantly reduce collagen deposition and inflammatory infiltration in lung tissues, reduce fibrosis area, improve lung functions of patients with pulmonary fibrosis, inhibit lung fibroblast activation and inhibit fibrosis progress. The action mechanism of the gene is related to inhibition of expression of BAG2, FN1, Collagen I and protein. The invention provides a brand new medicine choice for treating pulmonary fibrosis, has the unique advantage of new use of old medicine, and has the potential of short research and development period, known safety and definite curative effect. Meanwhile, the invention further expands the application of benzbromarone in preparation of the protein inhibitor and the in-vitro reagent.

The invention relates to application of indole-3-lactic acid in preparation of an acute pancreatitis resisting medicine, and belongs to the technical field of medicines. The invention provides an application of indole-3-lactic acid in preparation of an acute pancreatitis resisting medicine. An antibiotic mixture is used for conducting intragastric administration on a mouse, intestinal bacteria are removed, ILA and STS are subjected to intragastric administration on the mouse, leptofrog and arginine are injected into the abdominal cavity of the mouse for acute pancreatitis modeling, the acute pancreatitis resisting effect of ILA is studied, and the result shows that the amylase concentration in serum of the mouse subjected to intragastric administration of ILA is remarkably reduced; compared with STS, the ILA has the advantages that pancreatic tissue alveolar cell damage and inflammatory infiltration are obviously reduced, inflammatory cytokines in pancreatic tissue and serum are obviously reduced, and compared with STS, the ILA has a better protection effect, so that the ILA has the effect of resisting acute pancreatitis, and a new treatment way is provided for preventing and treating acute pancreatitis.